The full-service IP litigation team at Latham & Watkins is reputed for its technical expertise in healthcare and biotechnology, as well as the ability to achieve favourable results for clients in PTAB’s proceedings, including Inter Partes Review (IPR), Post Grant Review (PGR), and Covered Business Method (CBM). The team has a strong ITC practice, holding a particularly strong record in trade enforcement actions. Gabriel K. Bell, head of the firm’s IP appellate practice based in Washington D.C., remains a leading patent attorney with a strong appeals record before the Federal Circuit, recognised for his expertise in patent eligibility. Another notable attorney is Rachel Renee Blitzer, who brings her extensive trial experience to litigate on behalf of clients in complex high-tech matters. She is also well-regarded for her work beyond the courtroom, including IP licencing and robust due diligence. Prominent IP litigator Doug Lumish has left the firm.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Sector knowledge
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
‘Excellent depth of experience; great technical knowledge; creative.’
‘Well-rounded - not just experienced litigators, but also possess a depth of technical knowledge; worked well within the constraints required by my company; willing to work with my company to put a suitable alternate fee arrangement in place.’
‘Unparalleled strength in litigation strategy and execution. In-depth understanding of technology combined with insight in and foresight of legal scenarios and how to address them early. Extremely pleasant team to work with. ’
‘Roger Chin is the most thoughtful and insightful IP litigator I have ever worked with. The embodiment of calm and logic in the most difficult and stressful situations. His knowledge of medical matters and complex technology is a key factor in our litigation success. Roger's court appearances are brilliant with respect to his way of presenting arguments logically and convincingly.'
- 'Matt Moore is an excellent IP litigation leader and strategist. Matt has been extremely supportive with orchestrating the best of his team for our case.'
- 'Ashley Fry is a new brilliant addition to the team. She presented us very successfully in some key pleadings.’
Key clients
- Sarepta Therapeutics Inc.
- Abbott
- Amphenol Corp.
- Regeneron Pharmaceuticals, Inc.
- NETGEAR, Inc. and Estelgia, Inc.
- Recor Medical, Inc.
- fuboTV Inc.
- AbbVie Inc., Allergan, Inc., and Pharmacyclics LLC
- Johnson & Johnson, Janssen Biotech, Inc, and Actelion
- Lam Research Corporation
- Biogen Inc.
- Arista Networks
Work highlights
Achieved a trial victory representing Sarepta Therapeutics and the University of Western Australia (UWA), a biotechnology company and a research institution, in a patent litigation against Nippon Shinyaku (NS) and filed in the U.S. District Court for the District of Delaware.
Secured a significant trial for Abbott in its ongoing patent litigation against its main competitor, Dexcom, related to their continuous glucose monitors (CGMs).
Secured a settlement for Actelion, a Johnson & Johnson affiliate, in patent litigation against Bristol-Myers Squibb and Celgene.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Michael Morin; David Frazier; Charles Sanders; Patricia Young; Gabriel K. Bell
Other key lawyers
Rachel Renee Blitzer; Matt Moore; Roger Chin; Ashley Fry